Hazardous to Our Health?: FDA Regulation of Health Care ProductsRobert Higgs The US Food and Drug Administration (FDA) is one of the most powerful of federal regulatory agencies, if not the most powerful, regulating about 25 per cent of all consumer goods in the United States. It routinely makes decisions that determine the well-being of millions of people in the United States and around the world concerning foods, drugs, medical devices, and dietary supplements. Although the FDA was created to protect the public, could its actual operations have the opposite effect, causing enormous harm to public health? Assembling the work of three outstanding scholars, Hazardous to Our Health? provides a lucid and comprehensive examination of the FDA: How has the FDA acquired its vast powers? What have been the effects of the FDA? Why has the FDA failed to achieve its goals? Who actually benefits and loses from the FDA? How has the FDA defended itself against criticism? What real alternatives exist to the FDA? and much more. Hazardous to Our Health? goes beyond mere assumptions, conjectures, and political predilections to examine the facts and findings of independent authorities. Providing far more than just an account of the past and a warning for the future, this powe |
Contents
Introduction | 1 |
FDA Regulation of the Pharmaceutical Industry | 13 |
FDA Advertising Restrictions Ignorance Is Death | 29 |
Copyright | |
4 other sections not shown
Other editions - View all
Common terms and phrases
actions advertising and promotion agency agency's applications approval process aspirin authority benefits breast implants brief summary bureaucrats ceutical claims clinical trials compliance Congress congressional consumers cost court criticism David Kessler deception decisions defibrillator device companies device firms Diagnostics & Instrumentation Dingell Dingell's disease Drug Advertising drug lag Economics Emergency Medical Services enforcement Evaluation evidence example FDA approval FDA officials FDA regulation FDA's Food and Drug Foreword harm heart attack HIMA Hutt and Merrill increased innovation Institute issue Kahan Kessler Lasagna major manufacturers MDRs Medical Devices medical technology medicine Nobel off-label patients percent Peter Barton pharma pharmaceutical advertising pharmaceutical industry physicians Physio-Control Political premarket quoted reduce regulatory result risk Robert Higgs Rogaine Rubin safety standards therapeutic therapies tion U.S. House U.S. Stat University violations Wall Street Journal